Skip to main content
SpringerLink
Log in

In vivo efficacy of recombinant leukotactin-1 against cyclophosphamide

  • Published:
Biotechnology and Bioprocess Engineering Aims and scope Submit manuscript

Abstract

Leukotactin-1 (Lkn-1), a human CC chemokine, has been demonstrated to induce chemotaxis of neutrophils, monocytes, eosinophils and lymphocytes and has been shown to suppress colony formation of hematopoietic stem and progenitor cells (HSPC)in vitro andin vivo. The temporal suppression of HSPC by chemokines could potentially be applicable for various indications, such as the protection of HSPC from the several anti-proliferating chemotherapeutics in cancer treatments. In order to evaluate the protective effects on myeloid progenitor cells, the recombinant Lkn-1 was produced byPichia pastoris and tested with cyclophosphamide, cytotoxic chemotherapeutics. The pretreatment of Lkn-1 increased the number of HSPC in bone marrow as well as the potency of resulting progenitor cells after the treatment of cyclophosphamide. After the first cycle of cyclophosphamide treatment these protections of HSPC correlated with the increased number of white blood cells and neutrophils in the peripheral blood. In lethal conditions created by the repeated aministration of cyclophosphamide, the treatment of Lkn-1 enhanced the survival of mice, suggesting the potential use of Lkn-1 as the protective agent for HSPC from various cytotoxic insults.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Murdoch, C. and A. Finn (2000) Chemokine receptors and their role in inflammation and infectious diseases.Blood 95: 3032–3043.

    CAS  Google Scholar 

  2. Rollins, B. J. (1997) Chemokines.Blood 90: 909–928.

    CAS  Google Scholar 

  3. Nelson, P. J. and A. M. Krensky (2001) Chemokines, chemokine receptors, and allograft rejection.Immunity 14: 377–386.

    Article  CAS  Google Scholar 

  4. Baggiolini, M. (1998) Chemokines and leukocyte traffic.Nature 392: 565–568.

    Article  CAS  Google Scholar 

  5. Luster, A. D. (1998) Chemokines: Chemotactic cytokines that mediate inflammation.New Engl. J. Med. 338: 436–445.

    Article  CAS  Google Scholar 

  6. Youn, B. S., C. Mantel, and H. E. Broxmeyer (2000) Chemokines, chemokine receptors and hematopoiesis.Immunol. Rev. 177: 150–174.

    Article  CAS  Google Scholar 

  7. Szekanecz, Z. and A. E. Koch (2001) Chemokines and angiogenesis.Curr. Opin. Rheumatol. 13: 202–208.

    Article  CAS  Google Scholar 

  8. Gerard, C. and B. J. Rollins (2001) Chemokines, and disease.Nat. Immunol. 2: 108–115.

    Article  CAS  Google Scholar 

  9. Detheux, M., L. Standker, J. Vakili, J. Munch, U. Forssmann, K. Adermann, S. Pohlmann G. Vassart, F. Kirchhoff, M. Parmentier, and W. G. Forssmann (2000) Natural proteolytic processing of hemofiltrate CC chemokine 1 generates a potent CC chemokine receptor (CCR)1 and CCR5 agonist with anti-HIV properties.J. Exp. Med. 192: 1501–1508.

    Article  CAS  Google Scholar 

  10. Youn, B. S., S. M. Zhang, E. K. Lee, D. H. Park, H. E. Broxmeyer, P. M. Murphy, M. Locati, J. E. Pease, K. K. Kim, K. Antol, and B. S. Kwon (1997) Molecular cloning of leukotactin-1: A novel human beta-chemokine, a chemoattractant for neutrophils, monocytes, and lymphocytes, and a potent agonist at CC chemokine receptors 1 and 3.J. Immunol. 159: 5201–5205.

    CAS  Google Scholar 

  11. Zhang, S., B. S. Youn, J. L. Gao, P. M. Murphy, and B. S. Kwon (1999) Differential effects of leukotactin-1 and macrophage inflammatory protein-1 alpha on neutrophils mediated by CCR1.J. Immunol. 162: 4938–4942.

    CAS  Google Scholar 

  12. Gilmore, G. L., D. K. DePasquale, and R. K. Shadduck (1999) Protective effects of BB-10010 treatment on chemotherapy-induced neutropenia in mice.Exp. Hematol. 27: 195–202.

    Article  CAS  Google Scholar 

  13. Graham, G. J., E. G. Wright R. Hewick, S. D. Wolpe, N. M. Wilkie, D. Donaldson, S. Lormore, and I. B. Pragnell (1990) Identification and characterization of an inhibitor of haemopoietic stem cell proliferation.Nature 344: 442–444.

    Article  CAS  Google Scholar 

  14. Lord, B. I. (1995) MIP-1 alpha increases the self-renewal capacity of the hemopoietic spleen-colony-forming cells following hydroxyurea treatmentin vivo.Growth Factors 12: 145–149.

    Article  CAS  Google Scholar 

  15. Eaves, C. J., J. D. Cashman, S. D. Wolpe, and A. C. Eaves (1993) Unresponsiveness of primitive chronic myeloid leukemia cells to macrophage inflammatory protein 1 alpha, an inhibitor of primitive normal hematopoietic cells.Proc. Natl. Acad. Sci. USA 90: 12015–12019.

    Article  CAS  Google Scholar 

  16. King, R. J. B. (2000)Cancer Biology. 2nd ed., pp. 233–259. Pearson Education, Edinburgh Gate, UK.

    Google Scholar 

  17. Kim, W. Y., H. E. Broxmeyer, I. S. Han, D. H. Park, K. M. Lee, D. S. Vinay, and B. S. Kwon (2003) Effect of leukotactin-1 on the protectionin vivo of myeloid progenitor cells against cytotoxic chemotherapeutics.J. Hematother. Stem Cell Res. 12: 107–113.

    Article  CAS  Google Scholar 

  18. Christopherson, K. and R. Hromas (2001) Chemokine regulation of normal and pathologic immune responses.Stem Cells 19: 388–396.

    Article  CAS  Google Scholar 

  19. Marshall, E., L. B. Woolford, and B. I. Lord (1997) Continuous infusion of macrophage inflammatory protein MIP-1alpha enhances leucocyte recovery and haemopoietic progenitor cell mobilization after cyclophosphamide.Br. J. Cancer 75: 1715–1720.

    CAS  Google Scholar 

  20. Lee, W. H., S. H. Kim, E. M. Jeong, Y. H. Choi, D. I. Kim, B. B. Lee, Y. S. Cho, B. S. Kwon, and J. E. Park (2002) A novel chemokine, leukotactin-1, induces chemotaxis, proatherogenic cytokines, and tissue factor expression in atherosclerosis.Atherosclerosis 161: 255–260.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Mogam Biotechnology Research Institute, 449-910, Kyonggi-Do, Korea

    Gue-Wha Lee, Kong Ju Lee, Eun Young Chun, In Whan Lim, Eun Kyoung Lee, Mu Rim Choi, Doo-Hong Park & Yeup Yoon

  2. Department of Biological Engineering, Inha University, 402-751, Incheon, Korea

    Gue-Wha Lee & Dong-Il Kim

Authors
  1. Gue-Wha Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kong Ju Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Eun Young Chun
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. In Whan Lim
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Eun Kyoung Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Mu Rim Choi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Dong-Il Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Doo-Hong Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Yeup Yoon
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yeup Yoon.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lee, GW., Lee, K.J., Chun, E.Y. et al. In vivo efficacy of recombinant leukotactin-1 against cyclophosphamide. Biotechnol Bioproc E 9, 7–11 (2004). https://doi.org/10.1007/BF02949315

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02949315

Keywords

Search

Navigation